TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is demonstrating encouraging clinical traction as its Cohort C data continue to trend favorably, with all 13 patients achieving complete donor chimerism as of August 27th, including two relapsed patients who responded after a third dose of TSC-101 and/or maintenance therapy. The 6-month relapse rate of about 20% across 14 patients remains attractive versus historic post-HSCT relapse rates of roughly 45% in MRD+ patients and 20% in MRD- patients, supporting the view that TSC-101 may meaningfully reduce residual leukemia and relapse risk. Continued data updates at ASH in 4Q:26 and a ≥1-year update in 2Q:27 could further validate the program and strengthen the company’s clinical and strategic position.

TScan Therapeutics is now a materially weaker investment case because management paused the company’s most advanced asset, ALLOHA-2/TSC-101, due to insufficient capital, removing the primary late-stage catalyst and forcing the thesis onto earlier, unvalidated in vivo TCR-T programs. Although the restructuring cuts headcount by about 75% and is expected to generate $55M of cumulative savings, the company’s $100M cash position only appears to fund operations into 4Q27, while key milestones such as preclinical data in 1Q27, the first IND in 3Q27, and Phase 1 initiation in 4Q27 still require additional capital or a partner. The negative outlook is driven by a shrinking near-term value base, elevated financing and execution risk, and the possibility that even encouraging clinical signals in Cohort C may not translate into organic commercial value without external support.